Guglielmetti, S., Mora, D., Gschwender, M., & Tamayo, E. (2011). Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebo-controlled study. Alimentary Pharmacology & Therapeutics, 33(10), 1123-1132.
McFarland, L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology: WJG, 16(18), 2202.
Szajewska, H., Skórka, A., & Dylag, M. (2013). Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Alimentary Pharmacology & Therapeutics, 37(5), 516-523.
Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology, 5(2), 111-125.
Tursi, A., Brandimarte, G., Giorgetti, G. M., Modeo, M. E., & Gigliobianco, A. (2011). Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 17(2), PI13-PI20.
Campieri, M., Rizzello, F., Venturi, A., & Poggioli, G. (2007). Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-antibiotic recurrence of Clostridium difficile–associated diarrhoea: a randomized, controlled study. Alimentary Pharmacology & Therapeutics, 25(2), 243-251.